Ligand Pharmaceuticals (NASDAQ:LGND) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Posted by Andrew Walz on Feb 17th, 2026

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). In a filing disclosed on February 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ligand Pharmaceuticals stock on January 5th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Purchased $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 2/3/2026.
Purchased $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 2/3/2026.
Purchased $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/3/2026.
Purchased $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 2/3/2026.
Purchased $1,001 – $15,000 in shares of Banco Santander (NYSE:SAN) on 2/3/2026.
Purchased $1,001 – $15,000 in shares of Leonardo (OTCMKTS:FINMF) on 2/3/2026.
Purchased $1,001 – $15,000 in shares of Costco Wholesale (NASDAQ:COST) on 1/30/2026.
Purchased $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 1/30/2026.
Purchased $1,001 – $15,000 in shares of Cloudflare (NYSE:NET) on 1/30/2026.
Purchased $1,001 – $15,000 in shares of AutoZone (NYSE:AZO) on 1/30/2026.

Ligand Pharmaceuticals Stock Performance

NASDAQ LGND traded up $3.68 on Tuesday, reaching $187.51. 123,438 shares of the stock were exchanged, compared to its average volume of 223,850. The firm has a market capitalization of $3.69 billion, a PE ratio of 90.58 and a beta of 1.14. Ligand Pharmaceuticals Incorporated has a one year low of $93.58 and a one year high of $212.49. The company’s 50-day simple moving average is $193.76 and its two-hundred day simple moving average is $182.92. The company has a current ratio of 24.69, a quick ratio of 24.30 and a debt-to-equity ratio of 0.47.

Institutional Investors Weigh In On Ligand Pharmaceuticals

Several institutional investors have recently made changes to their positions in LGND. Tudor Investment Corp ET AL bought a new position in Ligand Pharmaceuticals during the 3rd quarter valued at about $2,789,955,000. State Street Corp boosted its position in shares of Ligand Pharmaceuticals by 3.1% during the second quarter. State Street Corp now owns 749,754 shares of the biotechnology company’s stock valued at $85,232,000 after buying an additional 22,629 shares during the period. Congress Asset Management Co. grew its stake in shares of Ligand Pharmaceuticals by 3.0% during the third quarter. Congress Asset Management Co. now owns 667,311 shares of the biotechnology company’s stock valued at $118,207,000 after buying an additional 19,370 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Ligand Pharmaceuticals by 59.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 541,845 shares of the biotechnology company’s stock worth $95,982,000 after buying an additional 202,103 shares during the period. Finally, Franklin Resources Inc. raised its holdings in shares of Ligand Pharmaceuticals by 115.9% in the fourth quarter. Franklin Resources Inc. now owns 496,160 shares of the biotechnology company’s stock worth $93,809,000 after buying an additional 266,304 shares during the period. Institutional investors own 91.28% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on LGND shares. Citigroup started coverage on Ligand Pharmaceuticals in a research note on Tuesday, December 9th. They issued a “buy” rating and a $270.00 price objective for the company. Oppenheimer boosted their price target on shares of Ligand Pharmaceuticals from $190.00 to $250.00 and gave the stock an “outperform” rating in a research note on Monday, November 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Ligand Pharmaceuticals in a research report on Monday, December 29th. Benchmark raised their price target on Ligand Pharmaceuticals from $175.00 to $220.00 and gave the company a “buy” rating in a report on Friday, November 7th. Finally, HC Wainwright upped their price objective on Ligand Pharmaceuticals from $206.00 to $231.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Six analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $239.33.

View Our Latest Research Report on LGND

Insiders Place Their Bets

In other news, Director John W. Kozarich sold 467 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $195.91, for a total value of $91,489.97. Following the transaction, the director directly owned 43,187 shares in the company, valued at approximately $8,460,765.17. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Octavio Espinoza sold 1,804 shares of Ligand Pharmaceuticals stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $188.31, for a total transaction of $339,711.24. Following the sale, the chief financial officer owned 26,186 shares of the company’s stock, valued at $4,931,085.66. The trade was a 6.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 3,205 shares of company stock valued at $611,192. 7.00% of the stock is owned by company insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.

The company’s product offerings center around several core platforms.